

## Disposal of own shares


**Brussels (Belgium), 11 March 2022 – 20:00 (CET) – Regulated information**

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
04 March 2022	09:46:58	Stock Option Plan 2016	500	€ 67,24
07 March 2022	09:03:27	Stock Option Plan 2012	4.500	€ 32,36
07 March 2022	09:27:18	Stock Option Plan 2012	100	€ 32,36
07 March 2022	11:07:05	Stock Option Plan 2012	1.500	€ 32,36
08 March 2022	09:00:42	Stock Option Plan 2012	100	€ 32,36
09 March 2022	16:28:18	Stock Option Plan 2012	100	€ 32,36
09 March 2022	16:43:04	Stock Option Plan 2012	100	€ 32,36
09 March 2022	16:46:52	Stock Option Plan 2012	100	€ 32,36
10 March 2022	10:38:20	Stock Option Plan 2012	500	€ 32,36

In addition to these exercises, on 7 March 2022, in accordance with the vesting rules under its 2012 LTI plan, UCB SA has delivered for free a total of 2.000 UCB shares OTC to 2 members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 7 March 2022 was € 96,94.

This press release is available on UCB SA/NV's website via the following [link](#).



# UCB News

---

**For further information, contact UCB:**

**Investor Relations**

Antje Witte  
T +32 2 559 94 14  
[antje.witte@ucb.com](mailto:antje.witte@ucb.com)

**Corporate Communications**

Laurent Schots  
T+32 2 559 92 64  
[laurent.schots@ucb.com](mailto:laurent.schots@ucb.com)

**About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news

